U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Stage III Cutaneous Melanoma AJCC v7

MedGen UID:
454153
•Concept ID:
C2981926
•
Neoplastic Process
Synonym: Stage III Skin Melanoma AJCC v7

Definition

Stage III includes: Any T, N1-3, M0. Stage III is divided into three pathologic subgroups: IIIA, IIIB, and IIIC. There are no clinical subgroups for stage III. N1: Cutaneous melanoma with metastasis in one regional lymph node. N2: Cutaneous melanoma with metastases in 2-3 regional lymph nodes or in transit met(s)/satellite(s) without metastatic nodes. N3: Cutaneous melanoma with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s). M0: No detectable evidence of distant metastases. (from AJCC 7th Ed.) [from NCI]

Recent clinical studies

Etiology

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2021-003272. PMID: 34599031Free PMC Article

Therapy

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ
J Immunother Cancer 2021 Oct;9(10) doi: 10.1136/jitc-2021-003272. PMID: 34599031Free PMC Article
Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ, Shirai K
J Immunother 2019 May;42(4):136-141. doi: 10.1097/CJI.0000000000000265. PMID: 30933044

Supplemental Content

Table of contents

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...